Vincent Med (01612.HK) announced that its wholly-owned subsidiary, Dongguan Vincent Med Products, recently received a 'No Action Indicated' rating following a risk-based work plan review conducted by the US Food and Drug Administration (FDA).

The related review is aimed at ventilator manufacturers, focusing on a risk-based secondary quality system inspection plan. During the 5-day review, representatives from the US Food and Drug Administration reviewed the operation, production processes, and regulations of Dongguan Vincent Med Products, confirming compliance with relevant document requirements and manufacturing standards.

Chairman of Vincent Med, Cai Wencheng, stated that passing this review and the rating obtained not only confirms the company's strict requirements for production processes and product quality, but also helps the company continue to enhance its market position. (js/w)

~